Findings

What do systematic reviews say?

3 questions · 3 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%

TRIFLUOPERAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Acceptability of treatment ‐ leaving the study early · patients with schizophrenia

Trifluoperazine showed no clear difference in leaving the study early: 1. Acceptability of treatment ‐ leaving… compared with low‐potency antipsychotic drugs (low certainty).

1 finding from 1 review

Trifluoperazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
RR 1.25 [0.72, 2.17]
3 studies · 239 participants
Low

TRIFLUOPERAZINE vs placebo

Leaving the study early · patients with schizophrenia

It is very uncertain whether TRIFLUOPERAZINE changes leaving the study early ‐ any reason ‐ medium term Number of… compared with PLACEBO (very low certainty).

1 finding from 1 review

Trifluoperazine versus placebo for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.67 [0.38, 1.19]
5 studies · 523 participants
Very low

Zuclopenthixol dihydrochloride vs trifluoperazine

Leaving the study early · schizophrenia

1 finding from 1 review

Zuclopenthixol dihydrochloride for schizophrenia 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 72 participants
Very low